Table 2.
Serum Metabolic and Atherogenic Risk Profile by Presence of Fatty Liver Disease
| Variable | Total (N = 114) | No FLD (n = 80) | FLD (n = 34) | P |
|---|---|---|---|---|
| Total cholesterol (mg/dL) | .23 | |||
| Median (IQR) | 162.5 (146–197) | 159.5 (145–195.5) | 173.5 (148–206) | |
| Low density lipoprotein | ||||
| LDL-C, n | 113 | 79 | 34 | .11 |
| Median (IQR), mg/dL | 96 (78–17) | 91 (76–112) | 98 (81–126) | |
| LDL-P, n | 105 | 75 | 30 | <.001 |
| Median (IQR), nmol/L | 1123 (625–1428) | 1043 (896–1290) | 1429 (1163–1744) | |
| sdLDL-C, n | 112 | 79 | 33 | <.001 |
| Median (IQR), mg/dL | 32 (23–43.5) | 29 (21–38) | 44 (32–56) | |
| Small LDL-P, n | 90 | 61 | 29 | .001 |
| Median (IQR), nmol/L | 633 (436–872) | 553 (387–722) | 912 (498–989) | |
| Very low density lipoprotein | ||||
| Triglycerides, n | 85 | 58 | 27 | <.001 |
| Median (IQR), mg/dL | 114 (77–171) | 100.5 (68–141) | 171 (101–261) | |
| apoB, n | 72 | 50 | 22 | .028 |
| Median (IQR), mg/dL | 83 (71–103.5) | 80.5 (70–94) | 95.5 (81–107) | |
| High density lipoprotein | ||||
| HDL-C, n | 114 | 80 | 34 | .12 |
| Median (IQR), mg/dL | 45 (37–55) | 46 (38.5–56.5) | 40.5 (36–50) | |
| HDL-P, n | 104 | 75 | 29 | .94 |
| Median (IQR), μmol/L | 31.2 (26.7–36.2) | 31.1 (27.2–36.2) | 31.6 (25.4–36.0) | |
| HDL-2-C, n | 111 | 79 | 32 | .001 |
| Median (IQR), mg/dL | 11 (7–17) | 12 (8–18) | 8.5 (6–11.5) | |
| apoA1, n | 72 | 50 | 22 | .60 |
| Median (IQR), mg/dL | 124.5 (108–143.5) | 122 (110–151) | 125.5 (100–139) | |
| Insulin sensitivity | ||||
| Glucose, n | 88 | 61 | 27 | .12 |
| Median (IQR), mg/dL | 90 (82.9–99.5) | 89 (82–97) | 94 (85–111) | |
| Insulin, n | 78 | 54 | 24 | <.001 |
| Median (IQR), μU/mL | 11 (7–19) | 8.5 (5–14) | 19 (11.5–31.5) | |
| Free fatty acids, n | 72 | 50 | 22 | .21 |
| Median (IQR), mmol/L | 0.47 (0.30–0.61) | 0.39 (0.29–0.56) | 0.49 (0.33–0.71) | |
| HOMA-IR, n | 75 | 51 | 24 | <.001 |
| Median (IQR) | 2.4 (1.5–4.9) | 2.0 (1.2–3.3) | 5.0 (2.6–9.2) | |
| Adipo-IR, n | 72 | 50 | 22 | <.001 |
| Median (IQR) | 34.7 (15.8–58.8) | 26.7 (14.1–36.7) | 71.3 (49.3–100.8) | |
| Metabolic | ||||
| Homocysteine, n | 112 | 79 | 33 | .48 |
| Median (IQR), μmol/L | 12 (9–14) | 11 (9–14) | 12 (10–14) | |
| Adiponectin, n | 62 | 46 | 16 | .15 |
| Median (IQR), μg/mL | 10 (7–15) | 11 (7–15) | 8.5 (6.5–11) | |
| Inflammatory | ||||
| hs-CRP, n | 109 | 78 | 31 | .90 |
| Median (IQR), mg/L | 2.0 (1.0–6.8) | 2.0 (1.0–7.0) | 2.1 (0.9–5.8) | |
| LP-PLA2, n | 111 | 78 | 33 | .74 |
| Median (IQR), nmol/minute/mL | 161 (125–191) | 165 (125–189) | 160 (133–197) |
Abbreviations: Adipo-IR, adipose tissue insulin resistance; apo, apolipoprotein; FLD, fatty liver disease; HBV, hepatitis B virus; HDL-2-C, HDL subclass 2-C; HDL-C, HDL cholesterol; HDL-P, HDL particle; HOMA-IR, Homeostasis Model Assessment Method Index; hs-CRP- high-sensitivity C-reactive protein; IQR, interquartile range; LDL-C, LDL cholesterol; LDL-P, LDL particle; LP-PLA2, lipoprotein-associated phospholipase A2; sdLDL-C, small, dense LDL cholesterol.